Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03328273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03328273 · ClinicalTrials.gov record · last posted 2026-07-14

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Name: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) — clinical trial record (NCT03328273)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorAcerta Pharma BV

Started2018-01-31

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2017-10-30; most recent amendment 2026-07-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-03-16

Status change Recruiting→Active, Not Recruitingv11

2018-02-16

Status change Not Yet Recruiting→Recruitingv3

Trial Details

NCT Number	NCT03328273
Lead Sponsor	Acerta Pharma BV
Conditions	Chronic Lymphocytic Leukemia
Enrollment	12 participants
Start Date	2018-01-31
Primary Completion	2021-09-07 (estimated)
Study Completion	2026-08-26 (estimated)
Updated on ClinicalTrials.gov	2026-07-14